ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) GREENHOUSE GAS EMISSIONS Neuren’s small workforce of 19 people all work from home and no office or other facility is maintained. Neuren engaged a third-party to confirm Neuren’s Scope 1 and 2 operational emissions for the year ended 31 December 2024. The emission boundary has been defined based on the operational control approach. Scope 1 emissions are direct Greenhouse Gas (GHG) emissions emitted from sources that are owned or controlled by the disclosing organisation, for example, emissions from combustion in owned or controlled boilers, furnaces, vehicles, or emissions from chemical production in owned or controlled process equipment. Scope 2 emissions are GHG emissions from the generation of purchased electricity consumed by the organisation. For the year ended 31 December 2024, Neuren had zero Scope 1 and 2 emissions, certified in accordance with The Greenhouse Gas Protocol – A Corporate Accounting and Reporting Standard, World Resources Institute/World Business Council for Sustainable Development (the GHG Protocol). SOCIAL IMPACT Neuren’s work to develop treatments for serious neurodevelopmental disorders that have no approved medicines and have a devastating impact on families potentially has a very high positive social impact, which is also highly motivating for Neuren’s workforce. Throughout its development programs, Neuren works closely with the patient communities for each of the disorders and provides financial support to events organised by patient advocacy organisations. DAYBUE, which is licensed by Neuren to Acadia Pharmaceuticals, is the only product in the world approved to treat Rett syndrome. It is widely available to Rett syndrome patients in the United States, at nominal cost to families through coverage by health insurance and government programs. Acadia is preparing for launch in Canada and Europe and conducting a clinical trial to support registration in Japan. Neuren’s second product NNZ-2591 has the potential to be the first ever treatment for children with Phelan-McDermid and Pitt Hopkins syndromes. Neuren’s policy of full time working from home provides people with high flexibility and enables optimum work/ life balance. It also enables Neuren to engage highly skilled people wherever they are located. The small size of the team and relatively flat structure facilitates opportunities to experience and take responsibility for a broader range of activities than would typically be available in larger companies. CORPORATE GOVERNANCE STATEMENT Neuren’s board of directors (“Board”) aims to ensure that the Company and its subsidiaries (the “Group”) operates with a corporate governance framework and practices that promote an appropriate governance culture throughout the organisation and that are relevant, practical and costeffective for the current size and stage of development of the business. This Statement is current as at 31 March 2025 and has been approved by the Board of Neuren Pharmaceuticals Limited. This Statement provides a description of the framework and practices, laid out under the structure of the ASX Listing Rules and the Corporate Governance Principles (the “Principles”) and Recommendations (the “Recommendations”) 4th Edition. PRINCIPLE 1. LAY SOLID FOUNDATIONS FOR MANAGEMENT AND OVERSIGHT The Board is responsible for the overall corporate governance of the Group. The Board acts on behalf of and is accountable to the shareholders. The Board seeks to identify the expectations of shareholders as well as other regulatory and ethical expectations and obligations. The Board is responsible for identifying areas of significant business risk and ensuring mechanisms are in place to manage those risks adequately. In addition, the Board sets the overall strategic goals and objectives, and monitors achievement of goals. The Board appoints the principal executive officer, currently the Chief Executive Officer. The Board has delegated the responsibility for the operation and administration of the Group to the Chief Executive Officer and senior management. The Board ensures that the management team is appropriately qualified to discharge its responsibilities. Neuren Pharmaceuticals Limited Annual Report 2024 16
RkJQdWJsaXNoZXIy MjE2NDg3